Pal Miheller, Ph.D.
Affiliations: | 2007 | Semmelweis Egyetem, Hungary |
Area:
PathologyGoogle:
"Pal Miheller"Parents
Sign in to add mentor| Laszlo Herszenyi | grad student | 2007 | Semmelweis Egyetem | |
| (Csontanyagcsere valtozasok kortani hattere gyulladasos belbetegsegben.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Barkai LJ, Gonczi L, Balogh F, et al. (2024) Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years. Scientific Reports. 14: 14909 |
| Sánta A, Szántó KJ, Sarlós P, et al. (2020) Letter: suicide risk among adult inflammatory bowel disease patients. Alimentary Pharmacology & Therapeutics. 51: 1213-1214 |
| Molnár T, Miheller P, Sarlós P, et al. (2020) P817 Influence of inflammatory bowel diseases on depression and suicidal risk: a questionnaire-based survey Journal of Crohns & Colitis. 14 |
| Bor R, Fábián A, Matuz M, et al. (2019) Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease- A nationwide Hungarian cohort study. Expert Opinion On Biological Therapy |
| Bálint A, Rutka M, Kolar M, et al. (2018) Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicentre observational cohort. Expert Opinion On Biological Therapy |
| Bor R, Klaudia F, Miheller P, et al. (2018) DOP007 Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease Journal of Crohns & Colitis. 12 |
| Gonczi L, Gecse KB, Vegh Z, et al. (2017) Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort. Inflammatory Bowel Diseases |
| Bálint A, Rutka M, Végh Z, et al. (2017) Frequency and Characteristics of Infusion Reactions during Biosimilar Infliximab Treatment in Inflammatory Bowel Diseases: results from Central European nationwide cohort. Expert Opinion On Drug Safety |
| Molnár A, Csontos ÁA, Dakó S, et al. (2017) [Investigating the efficacy of nutrition therapy for outpatients with inflammatory bowel disease]. Orvosi Hetilap. 158: 731-739 |
| Milassin Á, Rutka M, Csontos ÁA, et al. (2017) What Is the Personal Experience of IBD Patients about Their Anti-TNF-Alpha Therapy? Health. 9: 1007-1018 |